Monopar Therapeutics Inc.MNPRNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 85% recommend buying.

Consensus Rating

Buy

13 analysts·Moderate coverage

85%

Rating Distribution

Strong Buy

00%

Buy

1185%

Hold

215%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 66% higher.

Bear Case

$85.00

+30%

Consensus

$108.38

+66%

Bull Case

$125.00

+91%

Price Range13 analysts

Low

Consensus

High

$85.00

$125.00

Current Target

Current Price

$65.48

Upside to Target

$42.90

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-3.23(10 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+5114.24%

EPS—

FY2028

Rev+263.21%

EPS—

FY2029

Rev+105.01%

EPS—

Earnings Surprises

Beat rate:67%(8/12 quarters)

Avg surprise:-27.9%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 9, 2026Morgan Stanley

Monopar Therapeutics initiated with an Overweight at Morgan Stanley

Target:$115.00

+81.4%from $63.40

Nov 14, 2025Raymond James

Raymond James Downgrades Monopar Therapeutics (MNPR) to Outperform

Target:$123.00

+41.4%from $87.01

Oct 13, 2025Barclays

Monopar Therapeutics initiated with an Overweight at Barclays

Target:$125.00

+42.3%from $87.82

Oct 6, 2025Raymond James

Monopar Therapeutics price target raised to $142 from $80 at Raymond James

Target:$142.00

+42.9%from $99.39

Oct 2, 2025Oppenheimer

Monopar Therapeutics price target raised to $115 from $77 at Oppenheimer

Target:$115.00

+35.7%from $84.73

Sep 29, 2025H.C. Wainwright

Monopar Therapeutics price target raised to $105 from $70 at H.C. Wainwright

Target:$105.00

+37.0%from $76.63

Sep 25, 2025Chardan Capital

Monopar Therapeutics price target raised to $85 from $60 at Chardan

Target:$85.00

+16.9%from $72.69

Sep 25, 2025Piper Sandler

Monopar Therapeutics price target raised to $95 from $76 at Piper Sandler

Target:$95.00

+30.7%from $72.69

Sep 24, 2025BTIG

Monopar Therapeutics price target raised to $104 from $87 at BTIG

Target:$104.00

+42.4%from $73.04

Sep 9, 2025BTIG

Monopar Therapeutics initiated with a Buy at BTIG

Target:$87.00

+93.6%from $44.93

Sep 2, 2025Raymond James

Monopar Therapeutics initiated with a Strong Buy at Raymond James

Target:$80.00

+135.8%from $33.93

Aug 26, 2025H.C. Wainwright

Monopar Therapeutics assumed with a Buy at H.C. Wainwright

Target:$70.00

+128.7%from $30.61

Nov 19, 2024UBS

Monopar Therapeutics (MNPR) PT Raised to $37 at Jones Trading

Target:$37.00

+94.6%from $19.01

Nov 11, 2024H.C. Wainwright

Monopar Therapeutics (MNPR) PT Raised to $22 at H.C. Wainwright

Target:$22.00

+39.2%from $15.81

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance